



Patent \$

Attorney Docket No. 1033018-000121

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Frank E. Blondino et al.

Application No.: 10/734,150

Filing Date: December 15, 2003

Title: AEROSOL FORMULATIONS AND  
AEROSOL DELIVERY OF  
BUSPIRONE, BUSPRENORPHINE,  
TRAIZOLAM, CYCLOBENZAPRINE  
AND ZOLPIDEM

## MAIL STOP AMENDMENT

Group Art Unit: 1616

Examiner: Mina Haghighatian

Confirmation No.: 2098

## AMENDMENT/REPLY TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is a reply for the above-identified patent application.

- ☐ A Petition for Extension of Time is enclosed.
- ☒ A Terminal Disclaimer and the ☐ \$ 65 ☒ \$ 130 fee per Disclaimer due under 37 C.F.R. § 1.20(d) are enclosed.
- ☐ Also enclosed is/are: \_\_\_\_\_
- ☐ Small entity status is hereby claimed.
- ☐ Applicant(s) requests continued examination under 37 C.F.R. § 1.114 and enclose the ☐ \$ 405 ☐ \$ 810 fee due under 37 C.F.R. § 1.17(e).
- ☐ Applicant(s) requests that any previously unentered after final amendments not be entered. Continued examination is requested based on the enclosed documents identified above.
- ☐ Applicant(s) previously submitted \_\_\_\_\_ on \_\_\_\_\_ for which continued examination is requested.
- ☐ Applicant(s) requests suspension of action by the Office until at least \_\_\_\_\_, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.

- ☐ A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (1809/2809) is also enclosed.
- ☒ No additional claim fee is required.
- ☐ An additional claim fee is required, and is calculated as shown below:

AMENDED CLAIMS					
	No. of Claims	Highest No. of Claims Previously Paid For	Extra Claims	Rate	Additional Fee
Total Claims	11	20	0	x \$ 50 (1202)	\$ 0
Independent Claims	2	3	0	x \$ 210 (1201)	0
<input type="checkbox"/> If Amendment adds multiple dependent claims, add \$ 370 (1203)					\$ 0
<b>Total Claim Amendment Fee</b>					<b>\$ 0</b>
<input type="checkbox"/> Small Entity Status claimed - subtract 50% of Total Claim Amendment Fee					0
<b>TOTAL ADDITIONAL CLAIM FEE DUE FOR THIS AMENDMENT</b>					<b>\$ 0</b>


- ☒ Charge \$130 to Deposit Account No. 02-4800 for the fee due for the Terminal Disclaimer.
- ☐ A check in the amount of \_\_\_\_\_ is enclosed for the fee due.
- ☐ Charge \_\_\_\_\_ to credit card for the fee due. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date July 23, 2008

By:

  
\_\_\_\_\_  
Fang Liu, Ph.D.  
Registration No. 51283



Patent  
Attorney's Docket No. 1033018-000121

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	<b>MAIL STOP AMENDMENT</b>
Frank E. BLONDINO et al.	)	
Application No.: 10/734,150	)	Group Art Unit: 1616
Filed: December 15, 2003	)	Examiner: Mina HAGHIGHATIAN
For: AEROSOL FORMULATIONS AND	)	Confirmation No.: 2098
AEROSOL DELIVERY OF	)	
BUSPIRONE, BUSPRENORPHINE,	)	
TRIAZOLAM, CYCLOBENZAPRINE	)	
AND ZOLPIDEM	)	

**RESPONSE UNDER 37 C.F.R. § 1.111 AND**  
**SUBMISSION OF TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated April 25, 2008, in connection with the above-identified patent application, Applicants provide the following remarks.